Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHealth Net regorafenib (Stivarga) Coverage Update …
    Ask Trek AI about this page
    ModifiedHealth NetPolicy CP PHAR.107

    Clinical Policy: Regorafenib (Stivarga)

    Customize your policy alerts

    Sign up for Health Net Policy CP PHAR.107 alerts

    Get alerted when Policy CP PHAR.107 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity criteria, authorization requirements, and approval durations for regorafenib (Stivarga) for FDA-approved and selected off-label oncology indications for Health Net lines of business.

    Policy Summary
    PayerHealth Net
    PolicyClinical Policy: Regorafenib (Stivarga)
    Policy CodePolicy CP PHAR.107
    Change Type2Q 2025 annual review — added indications and revised HCC criteria
    Effective DateDec 1, 2012
    Next Review Date
    Key ActionObtain prior authorization with supporting clinical documentation demonstrating criteria are met (including documentation of prior therapies and current response for continuation).
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    For HCC, removed requirement for Child-Pugh class A disease per NCCN.

    Added off-label criteria set for uterine sarcoma per NCCN.

    Commercial approval duration modified to 12 months or duration of request, whichever is less; continuation approvals consolidated to 12 months.

    Additional coverable cancers (gliosarcoma, H3-mutated high-grade glioma) were added.

    For hepatocellular carcinoma (HCC), the requirement for Child-Pugh class A disease was removed.

    An off-label criteria set for uterine sarcoma per NCCN was added.

    References were reviewed and updated as part of the 2Q 2025 annual review.

    12 monthsTypical commercial approval
    6 monthsMedicaid/HIM approval
    160 mgMax dose (days 1-21)
    40 mg tabProduct availability
    2Q 2025Annual review
    3New indications added

    Coverage Criteria for Regorafenib (Stivarga)

    Other diagnoses/indications

    H. Other diagnoses/indications (must meet 1 or 2):

    ANY of the following

    • For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid): follow the applicable no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace, and CP.PMN.255 for Medicaid.
    • If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to the applicable policy for recent label changes per line of business.
    • For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid): follow the applicable non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace, and CP.PMN.16 for Medicaid.
    • If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND none of the above apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

    Common Initial Therapy Requirements

    Continuation / Renewal Criteria

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for continuation of Stivarga (regorafenib). Prior authorization requirements have been updated per policy revisions; providers must submit required clinical documentation at the time of request. Coverage decisions remain subject to terms, member benefits, and eligibility. Non-covered indications: requests for uses that are not FDA‑approved or not supported by NCCN or peer‑reviewed literature (when applicable) may be denied.

    • Prior authorization required for continuation therapy
    • Prior authorization requirements updated — confirm current policy version and payer edits
    • Required clinical documentation must be provided (see criteria group below)
    • Coverage decisions remain subject to member benefit limitations and eligibility
    • Non‑covered indications risk if request lacks FDA approval or guideline/literature support
    Documentation Required

    Documentation Required

    Step Therapy and Prior-Line Requirements

    Coverage requirementDetails / Policy language
    Generic-first requirement for brand requests
    For brand Stivarga requests, member must use generic regorafenib if available unless contraindicated or clinically significant adverse effects are experienced.
    Indications requiring prior lines of therapy before regorafenib may be authorized
    Metastatic colorectal cancer: prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti‑VEGF therapy, and if RAS wild‑type an anti‑EGFR therapy (or systemic chemotherapy per Appendix B for pMMR/MSS).
    Gastrointestinal stromal tumor (GIST): disease previously treated with imatinib and sunitinib (or ripretinib/Qinlock if intolerant to sunitinib) unless contraindicated or clinically significant adverse effects.
    Hepatocellular carcinoma (HCC): prescribed as second‑ or subsequent‑line therapy; previously treated with sorafenib (per Appendix B/NCCN guidance).
    Continuation / renewal requirement
    For continuation requests, member must be currently receiving Stivarga via the benefit or have documentation of ≥30 days of therapy; member must be responding positively to therapy; brand requests must trial generic regorafenib if available unless contraindicated.
    IndicationTherapeutic alternatives / required prior lines
    Metastatic colorectal cancer (CRC)
    Examples of systemic chemotherapy and targeted agents per Appendix B: fluorouracil (5‑FU), irinotecan (Camptosar), oxaliplatin (Eloxatin), bevacizumab (Avastin), ramucirumab (Cyramza), trifluridine/tipiracil (Lonsurf), cetuximab (Erbitux), panitumumab (Vectibix), and checkpoint inhibitors where indicated (e.g., pembrolizumab) — prior exposure to fluoropyrimidine-, oxaliplatin-, and irinotecan‑based regimens, an anti‑VEGF, and if RAS wild‑type an anti‑EGFR is required before regorafenib per policy.
    Gastrointestinal stromal tumor (GIST)
    Prior treatment with imatinib (Gleevec) and sunitinib (Sutent); ripretinib (Qinlock) may be used if intolerant to sunitinib. Regorafenib may be used after progression on these agents; off‑label combination with everolimus noted after progression on approved therapies.
    Hepatocellular carcinoma (HCC)
    Regorafenib reserved as second‑ or subsequent‑line therapy after prior sorafenib per Appendix B/NCCN guidance; dosing and prior‑therapy requirements specified in criteria set.
    Other systemic regimens referenced
    Appendix B lists chemotherapy regimens that may be considered prior therapies in CRC and other settings (FOLFOX, CAPEOX, FOLFIRI, FOLFOXIRI, IROX) and relevant biologics/checkpoint inhibitors; these are examples of therapeutic alternatives that may be required prior to regorafenib depending on indication.

    Provider Requirements and Authorization Process

    Prior Authorization

    Prior authorization required with supporting clinical documentation

    Prior authorization is required for regorafenib (Stivarga) and must be supported by clinical documentation demonstrating that the applicable coverage criteria are met; refer to formulary, non‑formulary, and off‑label policies when applicable.

    • Follow line-of-business policies for formulary/non‑formulary routing as referenced in the policy (e.g., CP.CPA.190, HIM.PA.33, CP.PMN.255).
    Prior Authorization

    Prior authorization for continuation: show benefit, dosing and generic‑first compliance

    Prior authorization is required for continuation requests; the request must document a positive response to therapy and comply with dosing limits and formulary/generic‑first requirements.

    • New doses must not exceed 160 mg PO daily on days 1–21 of each 28‑day cycle unless supported by practice guidelines or peer‑reviewed literature with prescriber evidence.
    • For brand requests, trial/use of generic regorafenib is required if available unless contraindicated or clinically significant adverse effects are documented.

    Coding and Dose Limits

    Maximum daily dose — 160 mg/day
    Maximum daily dose160 mg/day (maximum recommended dose on days 1-21 of each 28-day cycle)
    Dosing schedule160 mg PO once daily for the first 21 days of each 28-day cycle
    Applicable indicationsSpecifies this maximum for CRC, GIST, and HCC dosing regimens

    Quantity Limits and Product Availability

    regorafenib (Stivarga) — product quantity/dose information (160)
    Product strengthTablet: 40 mg
    Quantity limit / dose unitRegorafenib (Stivarga) quantity limit documented as 160 (mg/day)
    Standard dosing regimen160 mg PO once daily (days 1-21 of a 28-day cycle)

    Definitions and Key Terms

    Stivarga / regorafenib — definition: oral multikinase/VEGFR inhibitor
    Drug class / mechanismOral multikinase inhibitor with activity against VEGF/VEGFR and other kinases
    Common brand/generic namesStivarga (regorafenib)
    Typical formulationOral tablet (40 mg)
    Child-Pugh — Child-Pugh score and classes
    Scoring overviewChild-Pugh score is determined by total points from five parameters: bilirubin, albumin, INR, ascites, and encephalopathy
    Class A5-6 points
    Class B

    Background

    Regorafenib (Stivarga) is an oral multikinase inhibitor with activity against vascular endothelial growth factor receptors (VEGFR) and other kinases. It is available as a 40 mg tablet and is indicated for certain previously treated metastatic cancers; dosing commonly used is 160 mg/day given orally for the first 21 days of each 28-day cycle. The drugs mechanism as a multi-kinase/VEGFR inhibitor underlies its use across colorectal cancer, GIST, hepatocellular carcinoma, and selected off-label oncology indications when criteria are met.

    Revision History

    2025-02-05policy_revision

    2Q 2025 annual review removed the Child-Pugh class A requirement for hepatocellular carcinoma (HCC) per updated NCCN guidance.

    2025-02-05policy_addition

    2Q 2025 annual review added an off-label criteria set for uterine sarcoma per NCCN.

    2025-02-05policy_additionLatest
    Policy Summary
    PayerHealth Net
    PolicyClinical Policy: Regorafenib (Stivarga)
    Policy CodePolicy CP PHAR.107
    Change Type2Q 2025 annual review — added indications and revised HCC criteria
    Effective DateDec 1, 2012
    Next Review Date
    Key ActionObtain prior authorization with supporting clinical documentation demonstrating criteria are met (including documentation of prior therapies and current response for continuation).
    SourceLink
    On This Page
    Coverage Criteria for Regorafenib (Stivarga)Common Initial Therapy RequirementsContinuation / Renewal CriteriaStep Therapy and Prior-Line RequirementsProvider Requirements and Authorization ProcessCoding and Dose LimitsQuantity Limits and Product AvailabilityDefinitions and Key TermsBackgroundRevision History

    Documentation required: medical records demonstrating current use of Stivarga or at least 30 days of therapy, evidence of clinical benefit/response, dosing history, rationale for any dose increase, and documentation of trial of generic regorafenib first (unless contraindicated or intolerance). Prescriber must supply supporting literature when requesting non‑FDA‑approved dosing.

    • Medical records showing current receipt of Stivarga via benefit or ≥30 days of therapy
    • Clinical documentation of positive response to therapy
    • Dosing history and dates of administration
    • If increasing dose, documentation that new dose does not exceed 160 mg daily on days 1–21 of a 28‑day cycle or peer‑reviewed evidence supporting higher/off‑label dosing
    • Evidence of trial of generic regorafenib or documentation of contraindication/intolerance

    Continuation / Renewal Criteria

    Covered when ALL of the following are met:

    ALL of the following

    • Member is currently receiving medication via the Centene benefit, or documentation supports that the member is currently receiving Stivarga for a covered indication and has received this medication for at least 30 days.
    • Member is responding positively to therapy (clinical improvement or disease control documented).
      • ANY of the following

        • New dose does not exceed 160 mg per day on days 1 to 21 of each 28‑day cycle.
        • New dose is supported by practice guidelines or peer‑reviewed literature for the relevant off‑label use (prescriber must submit supporting evidence).
    • For brand Stivarga requests, the member must use generic regorafenib first, if available, unless contraindicated or clinically significant adverse effects are experienced (prescriber must document contraindication/intolerance).
    • Prescribed regimen must be FDA‑approved or recommended by NCCN; for off‑label regimens, prescriber must provide supporting peer‑reviewed evidence.
    Documentation Required

    Continuation Therapy — Documentation

    Continuation therapy documentation: approval for continuation requires demonstration of ongoing benefit and adherence to dosing limits and generic‑first rules. For continuation, documentation must show member is currently receiving Stivarga via the benefit or has received it for at least 30 days.

    • Show ongoing clinical benefit or disease stabilization
    • Adherence to dosing limits (≤160 mg daily on days 1–21 of each 28‑day cycle unless supported by evidence)
    • Evidence of generic regorafenib trial or documented contraindication/intolerance
    • Duration of prior therapy (≥30 days) must be documented
    Prior Authorization

    Prior authorization criteria updated per 2Q 2025 policy revisions

    Policy revisions (2Q 2025) add indications and revise HCC criteria; prior authorization criteria and applicable coverage determinations should be applied consistent with these updates and state Medicaid provisions when they conflict.

    • For HCC the Child‑Pugh class A requirement was removed per NCCN (2Q 2025 update).
    • When state Medicaid coverage provisions conflict with this clinical policy, state Medicaid provisions take precedence.
    Step Therapy

    Generic‑first requirement for brand Stivarga requests

    For brand Stivarga requests, the member must use generic regorafenib if it is available unless there is a documented contraindication or clinically significant adverse effects.

    • This generic‑first requirement applies to initial and continuation requests per the policy language.
    Step Therapy

    Refer non‑listed or non‑formulary uses to no‑coverage/non‑formulary/off‑label policies

    If the requested use is not listed in this policy or the drug is non‑formulary, refer the request to the applicable no‑coverage, non‑formulary, or off‑label use policy for required prior treatment trials and routing.

    • Refer to CP.CPA.190, HIM.PA.33, CP.PMN.255 for formulary no‑coverage routing; CP.CPA.190, HIM.PA.103, CP.PMN.16 for non‑formulary routing; and CP.CPA.09, HIM.PA.154, CP.PMN.53 for off‑label use.
    Documentation Required

    Submit office notes, labs, and other clinical documentation with PA requests

    Providers must submit supporting clinical documentation (for example, office chart notes, laboratory results, or other clinical information) to demonstrate the member meets the policy approval criteria.

    • Include relevant prior therapy history, response assessments, and rationale for off‑label dosing when applicable.
    Denial Risk

    Denial risk if required documentation is not provided

    Failure to submit required documentation (office notes, lab results, or other clinical information) supporting that the member has met all approval criteria may result in denial of the request.

    • Ensure documentation of prior therapies, current response, and any contraindications to generic therapy are provided.
    Denial Risk

    Non‑FDA indications require off‑label documentation per policy

    Requests for indications that are not FDA‑approved and not addressed in this policy are not authorized unless sufficient documentation of efficacy and safety is provided per the applicable off‑label use policy.

    • Off‑label requests must meet the off‑label policy documentation standards (e.g., CP.CPA.09, HIM.PA.154, CP.PMN.53).
    Note

    Coverage subject to benefit terms, exclusions, and state Medicaid precedence

    Coverage decisions are subject to the terms, conditions, exclusions, and limitations of the member’s benefit documents; policy determinations may be denied if contract terms are not met.

    • When state Medicaid provisions conflict with this policy, state Medicaid rules take precedence.
    Note

    Contract terms reminder and prohibited unauthorized use

    Providers and members are bound by the contractual terms and conditions expressed in their agreements; unauthorized copying, use, or distribution of this clinical policy is prohibited.

    • By providing services or submitting claims, providers and members agree to be bound by these terms.
    7-9 points
    Class C10-15 points
    progressive (per NCCN) — Progressive disease qualifier per NCCN
    Definition sourcePer NCCN disease qualifier referenced in policy update
    Meaning in policy context'Progressive' refers to disease progression as defined by NCCN guidance used to qualify certain indications
    RelevanceUsed to determine eligibility for off-label and updated CNS/HCC indications per 2Q 2025 policy revisions

    2Q 2025 annual review added additional coverable central nervous system cancer indications including gliosarcoma and H3‑mutated high‑grade glioma.